There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
HOME > REGULATORY
REGULATORY
- 26 Suspected Violations in Detailing Activities Reported in FY2021: MHLW
August 12, 2022
- Nippon Shinyaku’s MonoVer Iron Deficiency Drug Skips August Listing
August 12, 2022
- Katsunobu Kato Makes Yet Another Comeback as Health Minister
August 10, 2022
- Chuikyo OKs Lagevrio, Voxzogo, Enjaymo, and More for August Listing, BioMarin Med with Biggest Peak Sales Outlook
August 10, 2022
- Rybelsus Faces 2.5-2.6% Price Cut in November under CEA Scheme; No Change for Cabometyx
August 10, 2022
- Deliberations Underway for Transfer of Some MHLW Functions to Boost Pandemic Responses: Vice Health Minister
August 10, 2022
- Japan to Begin BA.1-Based Omicron Booster Program as Early as October
August 9, 2022
- MHLW to Set Up Panel to Promote Biosimilars as Early as Next Year: Official
August 9, 2022
- E Keppra Now Eligible for Health Coverage for Status Epilepticus
August 8, 2022
- No Major Safety Concerns for COVID-19 Vaccines in Japan: MHLW Panels
August 8, 2022
- LDP Project Team to Make Proposals for Japan-Moderna Deal
August 8, 2022
- MHLW Panel Members Support Silgard 9 HPV Vaccination for Ages 9-14
August 5, 2022
- Chuikyo OKs Insurance Coverage for CureApp’s Hypertension Therapeutic App
August 5, 2022
- MHLW Panel OKs Onoact for Pediatric Tachyarrhythmia and More Drugs
August 5, 2022
- Evaluate Shionogi COVID Pill Based on Omicron Symptoms: Komeito Lawmakers
August 5, 2022
- Janssen’s CAR-T Therapy, Kymriah Label Expansion Now in Line for Approval
August 4, 2022
- Chuikyo Will Consider Any Proposals of New Panel on Drug Pricing: Pharma Management Director
August 3, 2022
- Japan Approves KM Biologics’ Smallpox Vaccine for Monkeypox
August 2, 2022
- Supply Chain Clause of Economic Security Law Now in Effect
August 2, 2022
- MHLW Presents Plan for Monkeypox Vaccinations with KM Biologics’ Jab
August 2, 2022
ページ
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…